Pro/Con: Should patients taking SGLT2 inhibitors be dropped from the elective surgical program?
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have proven to play a key role as pleiotropic drugs beyond treatment of type 2 diabetes mellitus, promoting cardiovascular and renal-protective benefits even in non-diabetic patients. Moreover, SGLT2i have stepped into the spotlight in management of patients with heart failure with a preserved ejection fraction and chronic kidney diseases. Empagliflozin reduced event rates of myocardial infarction, cardiovascular death and strokes in type 2 diabetes mellitus patients compared to placebo, also decreasing hospitalization for cardiac failure [1].
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Sylvia Ryz, Clara Castellucci Tags: Pro and Con Source Type: research
More News: Anesthesia | Anesthesiology | Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Heart Attack | Heart Failure | Jardiance | SGLT2 Inhibitors | Sodium | Stroke | Urology & Nephrology